IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland

Pasquale Sansone,1,2 Gianluca Storci,1,3 Simona Tavolari,4 Tiziana Guarnieri,4 Catia Giovannini,1,5 Mario Taffurelli,6 Claudio Ceccarelli,1,7 Donatella Santini,7 Paola Paterini,4 Kenneth B. Marcu,1,8 Pasquale Chieco,1 and Massimiliano Bonafé1,3

1Center for Applied Biomedical Research, St. Orsola-Malpighi University Hospital, 2Department of Pharmacology and Toxicology, 3Department of Experimental Pathology, 4Department of Experimental Evolutionary Biology, 5Department of Internal Medicine and Gastroenterology, 6Department of Surgical and Anesthesiological Sciences, and 7Department of Radiological and Histopathological Sciences, University of Bologna, Bologna, Italy. 8Biochemistry Department, Stony Brook University, Stony Brook, New York, USA.

Introduction

IL-6, a major mediator of the inflammatory response, plays a primary role in the pathophysiology of cancer (1, 2). In breast cancer patients, the extent of the increase in serum IL-6 correlates with poor disease outcome and reduced prognosis (3, 4). Although it has been argued that the cytokine may be secreted by cancer cells, the source of the IL-6 in cancer patients has not yet been determined (5, 6). Cancer cells that are exposed to IL-6 or secrete the cytokine as an autocrine factor show malignant features, such as enhanced capacity to invade the extracellular matrix and increased drug resistance (7–10). Accordingly, the inactivation of the gp130 protein, which transduces the signaling of IL-6–type cytokines, has been found to reduce the aggressiveness of breast cancer cells in vivo (11). On the basis of these data, the inhibition of the IL-6/IL-6 receptor interaction with specific antibodies has been proposed as a support cancer therapy (12).

Breast cancer has been proposed as a stem cell disease (13). This hypothesis entails the notion that the growth of the tumor mass relies on the proliferation and self-renewal capacity of a small population of cancer-initiating cells known as cancer stem cells (13–16). Moreover, this notion helps elucidate why the dysregulation of stem cell regulatory pathways plays a causative role in breast cancer (15). In this regard, transgenic mice overexpressing isoforms of Notch, a signaling pathway active in stem cells, are more prone to develop mammary tumors (17). Further, high levels of Notch isoforms have been found to correlate with a poorer prognostic profile and reduced survival in breast cancer patients (18, 19).

Stem/progenitor cells of the mammary gland reside in the basal cell layer (20) and can be expanded in vitro from normal tissues as multicellular spheroids named mammospheres (MS) (21). Prior findings indicate that multicellular MS structures have a clonal origin and have the capacity to reform in vitro after trypsin dissociation (21). Bilineage (luminal and myoepithelial) progenitors are enriched up to 8 times in MS compared with freshly isolated human mammary cells and constitute virtually 100% of the cells in secondary MS (21, 22). MS regenerate and also form tubuloalveolar structures in matrigel and in immunodeficient mice cleared of fat pads (21–24). Similarly, MS from breast cancer tissues have been shown to proliferate in vitro and also generate tubuloalveolar structures composed of CD44+CD24− cells (25–27). Interestingly, the CD44+CD24− cell population has been shown to be extremely enriched in putative breast cancer stem cells (28).

Both normal and tumor MS (N-MS and T-MS, respectively) have been shown to require active Notch signaling to sustain their survival and proliferation capacity (24–26). Moreover, MS express gp130 and are potential targets of IL-6–type cytokines (21).

Here, we provide evidence that IL-6 gene expression is upregulated in MS obtained from aggressive ductal breast carcinomas and that IL-6 regulates a Notch–3–dependent signaling pathway that promotes self renewal, hypoxia survival, and the invasive potentials of N-MS and T-MS.

Nonstandard abbreviations used: CA-IX, carbonic anhydrase IX; CK, cytokeratin; DEX, desferoxamine; ER, estrogen receptor; IHC, immunohistochemistry; MCF-7(5), MCF-7–derived spheroid(5); MS, mammosphere(s); N-MS, normal MS; pNICD3, pCDNA3.1 vector encoding Notch-3 intracellular active cleaved fragment; shRNA, short hairpin RNA; T-MS, tumor MS.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 117:3988–4002 (2007). doi:10.1172/JCI32533.
The Journal of Clinical Investigation

The availability of N-MS and T-MS from the same patient allowed us to assess the level of IL-6 mRNA, accounting for variability caused by genetic makeup and age (30). We found that, compared with matched N-MS, T-MS from node-invasive tumors (pN3/pN2) expressed increased levels of IL-6 mRNA (Figure 1C). The same comparison performed on T-MS generated from scarcely node-invasive tumors (pNO/pN1) of ductal carcinomas revealed a negligible difference in IL-6 mRNA level between N-MS and T-MS (Figure 1C). Notably, compared with matched N-MS, T-MS obtained from patients affected by pN3/pN2 invasive tumors expressed similar levels of Bmi-1 and CK-5 mRNA and lower levels of breast cancer resistance protein 1 (BCRP-1) and CD133 mRNA, 2 antigens that have been previously associated with (cancer) stem cell phenotype (refs. 31–33; Figure 1C). The higher level of CD133 expression in N-MS compared with T-MS was also evident in IHC analysis (Supplemental Figure 4A).

We then assessed IL-6 mRNA in a set of archival breast tumor samples (Table 2), including ductal (n = 10) and basal-like (n = 6) breast carcinomas, a subtype of cancer showing stem cell features (34–37). This tumor type, similar to MS, was characterized by the expression of CK-5, CK-14, and EGFR protein as well as Bmi-1 and CD133 mRNA (Supplemental Figure 4, B and C), thereby reinforcing the notion of a tight similarity between MS and basal-like breast carcinoma cells (37).

In keeping with this reasoning, we detected IL-6 mRNA in basal-like breast carcinoma tissues, but not in ductal breast carcinoma (Figure 1D). These data indicate that IL-6 expression occurs in MS obtained from aggressive ductal breast carcinoma and in basal-like breast carcinoma tissues, wherein stem cell–like phenotypes are particularly apparent.

**IL-6 promotes MS self renewal and MCF-7–derived spheroid formation.** To assess the functional role of IL-6 expression in MS, we exposed secondary T-MS to a mAb that blocks the IL-6 receptor/ligand interaction (anti–IL-6; 1.5 μg/ml). Exposure of T-MS to anti–IL-6 substantially blunted their secondary regeneration capacity, a functional property that has been referred to as MS self-renewal capability (refs. 21, 22, 25; Figure 2A). Accordingly, we observed that administration of IL-6 (10 ng/ml) to N-MS and T-MS from the same patient yielded an increase in secondary MS formation compared with MS not exposed to the cytokine, a phenomenon that was hampered by the simultaneous addition of anti–IL-6 (1.5 μg/ml; Figure 2B). We further investigated this phenomenon in the context of MCF-7–derived spheroids [MCF-7(S)], which have been recently shown to contain a substantial proportion of CD44+/CD24– cells (38). MCF-7(S) expressed high levels of IL-6 mRNA, whereas the mRNA of the cytokine was absent in MCF-7 cells cultured in standard conditions (Figure 2C). Moreover, the administration of anti–IL-6 (1.5 μg/ml) caused a substantial reduction in MCF-7(S) size (Figure 2C). These data indicate that IL-6 mRNA expression promotes growth in suspension and that both autocrine and exogenous IL-6 promotes MS self renewal.

**The MCF-7(S) growth-promoting activity of IL-6 requires Notch-3 gene.** Notch genes play a pivotal role in MS self renewal (24–26). In particular, Notch-3 is highly expressed in N-MS and T-MS (21, 26), and its blockage induces a marked reduction in MS self renewal and survival (26). On these bases, we tested the hypothesis that the effect of IL-6 on MS self renewal and MCF-7(S) formation may depend upon Notch-3 gene expression. We found that administration of anti–IL-6 (1.5 μg/ml) to T-MS for 24 hours yielded down-regulation in the level of Notch-3 mRNA and that administration

---

**Table 1**

Clinical-pathologic parameters of 17 breast ductal carcinomas used for T-MS and N-MS generation

<table>
<thead>
<tr>
<th>Sample</th>
<th>Age (yr)</th>
<th>pT</th>
<th>pN</th>
<th>G</th>
<th>NG</th>
<th>ER</th>
<th>HER-2</th>
<th>EGFR</th>
<th>T-MS</th>
<th>N-MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>61</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
</tr>
<tr>
<td>2</td>
<td>85</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>+</td>
<td>1</td>
<td>–</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>3</td>
<td>73</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>+</td>
<td>–</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>4</td>
<td>46</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
</tr>
<tr>
<td>5</td>
<td>73</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>+</td>
<td>–</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>6</td>
<td>62</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>2</td>
<td>–</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>7</td>
<td>58</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>8</td>
<td>83</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>9</td>
<td>63</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>10</td>
<td>55</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>11</td>
<td>59</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>12</td>
<td>44</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>+</td>
<td>0</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>13</td>
<td>59</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>+</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>N</td>
</tr>
<tr>
<td>14</td>
<td>39</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>+</td>
<td>–</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>15</td>
<td>73</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>+</td>
<td>1</td>
<td>–</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>16</td>
<td>85</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>–</td>
<td>0</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>17</td>
<td>61</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>+</td>
<td>1</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
</tbody>
</table>

pT, tumor size; pN, nodal involvement; G, grading; NG, nuclear grading; HER-2: ErbB-2 receptor; Y, yes; NA, not available; N, no. mRNA from the tumor tissue was available.
of IL-6 (10 ng/ml) to N-MS for 24 hours elicited upregulation of Notch-3 mRNA (Figure 3A). A similar regulation was observed in MCF-7 cells and MCF-7(S) exposed to IL-6 (10 ng/ml for 24 hours) and in MCF-7(S) exposed to anti–IL-6 (1.5 μg/ml for 24 hours; Figure 3B). To better characterize the role of IL-6/Notch-3 interplay in substrate-independent growth, we generated MCF-7(S) using MCF-7 cells stably transduced with a retroviral vector expressing Notch-3–specific (shNotch-3) or control short hairpin RNA (shRNA). We found that MCF-7(S) obtained from control shRNA–transduced MCF-7 cells and generated in the presence of IL-6 (10 ng/ml) showed an increase in size, whereas shNotch-3 MCF-7 cells did not produce MCF-7(S), even in presence of exogenous IL-6 (10 ng/ml; Figure 3C). These data indicate that Notch-3 signaling is of pivotal importance to sustain the IL-6–dependent growth of breast cancer cells in suspension culture.

IL-6 elicits a Notch-3–dependent upregulation of Jagged-1 mRNA expression, which sustains MCF-7(S) formation and promotes MS self renewal. We recently reported that Notch-3 promotes MS survival by interacting with its ligand Jagged-1 (26). Therefore we next evaluated whether Jagged-1 was involved in Notch-3–dependent MS growth. Indeed, either exposing N-MS to IL-6 (10 ng/ml) or adding anti–IL-6 (1.5 μg/ml) to T-MS modulated the expression of Jagged-1 mRNA (Figure 4A). Moreover, we found that in MCF-7 cells, IL-6 elicited upregulation of Jagged-1 mRNA, which was blocked by the coadministration of IL-6 with the MEK/ERK inhibitor UO-126 (Figure 4B). Furthermore, we found that the upregulation of Jagged-1 induced by IL-6 was negligible in shNotch-3 MCF-7 cells and that the transfection of pCDNA3.1 vector encoding Notch-3 intracellular active cleaved fragment (pNICD3) into MCF-7 cells triggered an upregulation of Jagged-1 mRNA, which was prevented by the concurrent administration of UO-126 (Figure 4B). In addition, we observed that MCF-7(S) formation was extremely reduced when MCF-7 cells were transfected with a Jagged-1 specific siRNA compared with scrambled control siRNA (Figure 4C). Finally, we observed that an antibody blocking Jagged-1/Notch-3 interaction reduced MS regeneration capacity (Figure 4D), indicating that the Notch-3/Jagged-1 pathway is functionally relevant for IL-6–induced MS formation. Notably, we also found that basal-like breast carcinoma tissues expressed higher Jagged-1 and Notch-3 mRNA levels than did ductal breast carcinoma tissues (Figure 4E). These data suggest that upregulation of Jagged-1 via Notch-3 signaling is crucial for the growth in suspension of breast cancer cells and MS and that this phenomenon may also occur in basal-like breast cancer tissues.

IL-6 induces a Notch-3–dependent upregulation of carbonic anhydrase IX. ERK upregulation has recently been found to enhance the expression of the hypoxia survival gene carbonic anhydrase IX (CA-IX; refs. 26, 39). Thus given our above observations, we next evaluated whether IL-6 signaling modulates CA-IX mRNA expression. Indeed, adding IL-6 (10 ng/ml) to N-MS induced upregulation of CA-IX mRNA (Figure 5A). Increased CA-IX expression was also observed in MCF-7 cells exposed to IL-6 (10 ng/ml for 24 hours), whereas
CA-IX gene expression was markedly reduced by the administration of UO-126 (Figure 5B). Similar to what we observed for Jagged-1 (Figure 4B), CA-IX gene expression was inhibited in shNotch-3 MCF-7 cells, but not control MCF-7 cells, exposed to IL-6, while it was enhanced by transfection of the pNICD3 vector but not in the presence of UO-126 (Figure 5B). Because CA-IX is a hypoxia response gene (39), we investigated whether IL-6 plays a role in the hypoxia response. Exposure of MCF-7 cells to hypoxic stimuli (100 μM desferoxamine [DFX] or low oxygen tension, <0.1% O₂, for 48 hours), as well as the exposure of N-MS and T-MS to 50 μM DFX for 48 hours), enhanced the expression of IL-6, Notch-3, and CA-IX mRNAs (Figure 5C). Importantly, upon blocking the upregulation of hypoxia-responsive genes with 100 μM DFX, the administration of anti–IL-6 (1.5 μg/ml) to MCF-7 cells caused downregulation of Notch-3 and CA-IX mRNA. In addition, CA-IX mRNA was also downregulated in shNotch-3 MCF-7 cells exposed to 100 μM DFX compared with control MCF-7 cells (Figure 5D). Taken together, these results indicate that the CA-IX gene expression is regulated by the IL-6/Notch-3 pathway in MCF-7 cells and MS.

IL-6/Notch-3/CA-IX axis promotes hypoxia survival in MCF-7 and MS.

IL-6/Notch-3/CA-IX axis promotes hypoxia survival in MCF-7 and MS. CA-IX has been found to play a crucial role in hypoxia survival of breast cancer cells and MS (26). In keeping with these data, we observed a substantial increase compared with matched controls in cell death of MCF-7 cells exposed to 100 μM DFX in the presence of anti–IL-6 (1.5 μg/ml) or transfected with a CA-IX–specific siRNA (Figure 6A). Furthermore, a higher degree of hypoxia-induced cell death accompanied by downregulation of CA-IX mRNA was observed in shNotch-3 MCF-7 cells compared with control MCF-7 cells (Figure 6A). In line with these results, we found that exposure of T-MS to anti–IL-6 or anti-N3 (1.5 and 1 μg/ml, respectively) or transfection with CA-IX siRNA, in the presence of 50 μM DFX, increased cell death compared with a matched scrambled siRNA control (Figure 6B). Interestingly, detectable levels of CA-IX mRNA were found only in tissues from basal-like breast carcinoma (Figure 6C). These data indicate that IL-6/Notch-3–induced CA-IX gene expression promotes hypoxia survival in MS and support the similarity between the gene expression profiles of MS and basal-like breast carcinoma tissues.

IL-6 triggers a Notch-3/CA-IX–dependent increase in the invasiveness of MS and MCF-7 cells. The results illustrated in Figure 5B pointed out that IL-6 induces a Notch-3/ERK–mediated upregulation of CA-IX expression in absence of hypoxia. We then investigated the activity of the IL-6/Notch-3/CA-IX axis in normoxic conditions. We found that exposure to IL-6 (10 ng/ml) enhanced the capacity of MCF-7 cells to invade the extracellular matrix. This increase was negligible in shNotch-3 MCF-7 cells, and it was also substantially reduced when CA-IX, but not scrambled, siRNA was administered to IL-6–exposed MCF-7 cells (Figure 7A). In keeping with these observations, we found that administration of anti–IL-6 (1.5 μg/ml) or transfection of an IL-6–specific siRNA or CA-IX siRNA caused a substantial decrease in the invasive potential of T-MS compared with scrambled siRNA (Figure 7B). Further, the administration of IL-6 (10 ng/ml) enhanced the invasive potential of N-MS, yet this phenomenon was blocked by coadministration of anti-N3 (1.5 μg/ml) or transfection of CA-IX, but not scrambled, siRNA (Figure 7C). Parallel to these findings, we observed that IL-6 enhanced the activity of the extracellular matrix–degrading enzyme MMP-2 in control MCF-7 cells and in scrambled siRNA–transfected MCF-7 cells, but not in shNotch-3 MCF-7 cells or in CA-IX siRNA–transfected ones (Figure 7D). These data suggest that the IL-6/Notch-3–dependent upregulation of the CA-IX gene enhances the invasive behavior of MCF-7 cells and MS.

Autocrine IL-6 sustains a CA-IX–dependent aggressive phenotype in MCF-7–derived, hypoxia-selected cells. Taken together, these results suggest that the establishment of an autocrine IL-6 loop may engender cancer cells with a substantial growth advantage over their normal counterparts. To explore this idea, we next examined a MCF-7–derived cell population, HYPO-7, which was obtained by selecting parental MCF-7 cells in the presence of 100 μM DFX (see Methods). Such cells, cultured for an extensive time period (up to 1 year) in the absence of DFX were found to constitutively express high levels of IL-6, Notch-3, and CA-IX mRNA (Figure 8A). We found that, compared with scrambled siRNA, administration of IL-6 siRNA to HYPO-7 yielded a decrease in Notch-3 and CA-IX mRNA expression, an increase in the susceptibility to DFX–induced cell death, and a reduction in their invasive potential and MMP-2 activity (Figure 8A). In agreement with the data obtained in MCF-7 cells and MS, we found that the administration of CA-IX, but not scrambled, siRNA to HYPO-7 cells recapitulated the phenotypic changes induced by IL-6 siRNA in HYPO-7 cells (Figure 8B). Interestingly, the effects elicited by IL-6 siRNA were also observed when HYPO-7 cells were exposed to anti–IL-6 (1.5 μg/ml for 24 hours; data not shown). Of particular importance, however, was the observation that administration of anti–IL-6 (1.5 μg/ml for 24 hours) caused downregulation of IL-6 mRNA in HYPO-7 cells as well as in MCF-7(S) and T-MS (Figure 8C). These data sug-

---

### Table 2

Clinical-pathologic parameters of 16 archival breast carcinoma tissues assessed by RT-PCR

<table>
<thead>
<tr>
<th>Sample</th>
<th>Age (yr)</th>
<th>pT</th>
<th>pN</th>
<th>G</th>
<th>NG</th>
<th>ER</th>
<th>HER-2</th>
<th>CK-5</th>
<th>CK-14</th>
<th>EGFR</th>
<th>Histotype</th>
<th>Basal-like</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>40</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>55</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>71</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>47</td>
<td>4</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>E</td>
<td>78</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>65</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>57</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td>57</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>42</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>J</td>
<td>49</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>K</td>
<td>78</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>L</td>
<td>64</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>63</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>63</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>O</td>
<td>60</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>P</td>
<td>45</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>N</td>
<td></td>
</tr>
</tbody>
</table>

pT, tumor size; pN, nodal involvement; G, grade; NG, nuclear grade; HER-2: ErbB-2 receptor; IDC, infiltrating-ductal-breast carcinoma; Y, yes; N, no. Basal-like breast carcinomas were diagnosed as CK-5- and/or CK-14-, EGFR+, ER+, and HER-2–negative or –low (0 or 1) ductal breast carcinomas (34, 35).
gest that autocrine IL-6 production could promote the aggressiveness of breast cancer cells.

IL-6 induces an autocrine IL-6 loop that triggers Notch-3–dependent aggressive behavior in MCF-7 cells. Prompted by these observations, we reasoned that IL-6 might regulate the production of its own mRNA. Accordingly, we found that administration of IL-6 (10 ng/ml) upregulated IL-6 mRNA in MCF-7 cells and N-MS (Figure 9A). Furthermore, once exposed to IL-6 (10 ng/ml for 24 hours), MCF-7 cells expressed IL-6 mRNA, even 2 weeks after the withdrawal of IL-6 from the medium (Figure 9B), suggesting that IL-6 autoregulation might perpetuate phenotypic changes caused by exposing breast cancer cells to IL-6. Compared with untreated MCF-7 cells, the cells described above displayed upregulation of Notch-3 and CA-IX mRNA levels, paralleled by an enhancement in their invasive potential and an increase in MMP-2 activity (Figure 9B). The gene upregulation and the increase in invasive behavior of MCF-7 cells 2 weeks after withdrawal of IL-6 was abolished by administration of anti–IL-6 (1.5 μg/ml), indicating that such features were dependent upon an autocrine IL-6 loop (Figure 9C). Notch-3 signaling was also required for this effect, because shNotch-3 MCF-7 cells did not show upregulation in CA-IX mRNA nor an enhancement of invasive potential, which were both observed in control MCF-7 cells 2 weeks after exposure to IL-6 (Figure 9D). As expected, the enhanced invasive capacity of IL-6–treated control MCF-7 cells was reduced by the transfection of CA-IX siRNA, but not scrambled siRNA (Figure 9E). These data support the argu-
ment that an IL-6 autocrine loop could induce long-term enhancement in the aggressive features of breast cancer cells by sustaining upregulation of the Notch-3/CA-IX axis.

Discussion

The present work was prompted by the remarkably consistent finding that high IL-6 serum levels in breast cancer patients are associated with poor outcome and by the accumulating evidence suggesting that IL-6 exerts a direct role in the upregulation of malignant features in breast cancer cells (1–8). Herein we investigated the physiological effects and regulation of IL-6 in MS, which can be considered a suitable in vitro model for normal and tumor stem/progenitor cells of the mammary gland (21–27).

In regard to the stem cell phenotype of MS, we show here that MS express a variety of genes that are upregulated in normal and cancer stem cell from various tissues, such as Bmi-1 (23, 40), CD44 (28, 29), Oct-4 (27), BCRP-1 (33), and CD133 (31, 32). In particular, N-MS and T-MS are almost entirely composed of CD44+CD24− cells (the so-called breast cancer stem cell phenotype; refs. 27, 28, 41) and a subpopulation of cells (differing 10%–20% in N-MS and T-MS) expressing CD133 protein. Moreover, N-MS and T-MS express the CK-5 gene, which characterizes the basal cell compartment in which stem/progenitor cells of the mammary gland are harbored in vivo (20). In this regard, recent data suggest that CK-5/CD44+, Bmi-1–expressing cells represent cancer stem cells of head and neck squamous carcinoma (40). Overall, the available data support the notion that MS were substantially enriched in stem/progenitor cells compared with the tissues from which they were obtained.

We provide evidence that T-MS obtained from node-invasive tumors expressed higher IL-6 mRNA levels than MS obtained from normal tissue of the same patients. Conversely, no difference was found when MS from scarcely invasive tumors were examined. We also found that IL-6 mRNA levels were readily detected ex vivo only in CK-5+ basal-like breast carcinoma tissues, an uncommon form of biological aggressive breast carcinoma with stem cell–like features, including high levels of CD133 and CD44 expression (34–37). We also showed that these tumors expressed high levels of the stem cell regulatory gene Bmi-1, which was recently shown to be expressed at high levels in T-MS compared with their differentiated epithelial progeny (23). In addition, Bmi-1 is also upregulated in CD44+CD24− breast cancer cells (23) and is highly expressed in a CK-5/CD44+ subpopulation of putative head and neck squamous carcinoma cancer stem cells (40). We also document that like basal-like carcinoma cells, T-MS also expressed CK-5+/14, EGFR, CD133, Bmi-1, and IL-6. Thus T-MS derived from ductal breast carcinoma would appear to possess at least some of the stem cell–like characteristics of basal-like breast carcinoma. Our findings on basal-like breast carcinomas support the hypothesis that IL-6 gene expression is related to breast cancer stem cell phenotype. Accordingly, it has been shown that IL-6 gene expression is high in breast cancer cell lines enriched in CD44+CD24− invasive cells (16). Moreover, IL-6 gene expression showed up in MCF-7–derived spheroids (our present results), which have been shown to contain a high proportion of CD44+CD24− cells (38). Overall, these data support the existence of a tight relationship between cancer stem cells and IL-6 expression.

Figure 3

IL-6 induces Notch-3 gene upregulation and Notch-3–dependent MCF-7(S) formation. (A) RT-PCR analysis of Notch-3 mRNA in day 10 primary N-MS in the presence or absence of IL-6 (10 ng/ml) and in T-MS in the presence or absence of anti–IL-6 (1.5 μg/ml) for 24 hours. (B) RT-PCR analysis of Notch-3 mRNA in MCF-7 cells cultured in the presence or absence of IL-6 (10 ng/ml) and in MCF-7(S) in the presence or absence of anti–IL-6 (1.5 μg/ml) or IL-6 (10 ng/ml) for 24 hours. (C) Day 7 MCF-7(S) generated from MCF-7 cells infected with a pSuper-Puro retroviral vector encoding a Notch-3–specific (N3) or control (CT) shRNA (sh) in the presence or absence of IL-6 (10 ng/ml). Phase-contrast microscopy analysis, MCF-7(S) size distribution (n denotes number of spheroids counted per sample), and Western blot analysis of Notch-3 and β-actin protein levels. *P = 0.034, Monte Carlo χ² test. β²μ was assessed as quantitative control for RT-PCR analysis. Scale bars: 100 μm.
Moreover, we also provide evidence that the effects of IL-6 on MS required a functional Notch-3 signaling pathway. Notch-3, a member of the stem cell regulatory Notch family that governs stem cell homeostasis and turnover across species, modulates morphogenetic processes in the mammary gland; when hyperexpressed in transgenic mice, Notch-3 also promotes mammary gland carcinogenesis (17). Interestingly, the Notch-3–dependent activation of the ERK pathway has been reported in both lung cancer and lymphoma cell models (26, 42, 43). Here, we show that Notch-3–dependent ERK activation in breast cancer via IL-6 targeted the
simultaneously lowers the pH in the extracellular space, thereby reducing the concentration of basic equivalents in the cytoplasm, which facilitates survival under conditions of hypoxia by increasing the invasive capacity of breast cancer cells and MS. CA-IX catalyzes carbonic dioxide hydrolysis upregulated by IL-6 and sustained the invasive potential of breast cells and also to ductal breast carcinoma stem cells.

ged-1 axis may confer a growth advantage to basal-like carcinoma subtypes (34), we hypothesize that the IL-6/Notch-3/Jag cross-talk promotes the upregulation of CA-IX mRNA and protein. (A) RT-PCR analysis of CA-IX mRNA in day 10 primary N-MS cultured in the presence or absence of IL-6 (10 ng/ml) for 24 hours. (B) RT-PCR analysis of CA-IX mRNA and Western blot analysis of CA-IX (phosphorylated ERK, total ERK, and β-actin protein levels shown in Figure 4B) in MCF-7 cells exposed to IL-6 (10 ng/ml for 24 hours) in the presence or absence of UO-126 (20 μM) or DMSO, in shNotch-3 and control MCF-7 cells exposed to IL-6 (10 ng/ml for 24 hours), in MCF-7 cells transiently transfected with pNICD3/pEMPTY vector (1 μg), and in MCF-7 cells transfected with pNICD3 and coadministered with UO-126 (20 μM) or DMSO for 24 hours. (C) RT-PCR analysis of IL-6, Notch-3, and CA-IX mRNA in MCF-7 cells exposed to low oxygen (<0.1% O2) or 100 μM DFX and in N-MS and T-MS exposed to 50 μM DFX for 48 hours. (D) RT-PCR analysis of Notch-3 and CA-IX mRNA in MCF-7 cells in the presence or absence of anti-IL-6 (1.5 μg/ml) and in shNotch-3 and control-infected MCF-7 cells exposed to DFX (100 μM for 24 hours), Western blot analysis of Notch-3 and β-actin protein. β-2M was assessed as quantitative control for RT-PCR analysis.

Figure 5
IL-6/Notch-3 cross-talk promotes the upregulation of CA-IX mRNA and protein. (A) RT-PCR analysis of CA-IX mRNA in day 10 primary N-MS cultured in the presence or absence of IL-6 (10 ng/ml) for 24 hours. (B) RT-PCR analysis of CA-IX mRNA and Western blot analysis of CA-IX (phosphorylated ERK, total ERK, and β-actin protein levels shown in Figure 4B) in MCF-7 cells exposed to IL-6 (10 ng/ml for 24 hours) in the presence or absence of UO-126 (20 μM) or DMSO, in shNotch-3 and control MCF-7 cells exposed to IL-6 (10 ng/ml for 24 hours), in MCF-7 cells transiently transfected with pNICD3/pEMPTY vector (1 μg), and in MCF-7 cells transfected with pNICD3 and coadministered with UO-126 (20 μM) or DMSO for 24 hours. (C) RT-PCR analysis of IL-6, Notch-3, and CA-IX mRNA in MCF-7 cells exposed to low oxygen (<0.1% O2) or 100 μM DFX and in N-MS and T-MS exposed to 50 μM DFX for 48 hours. (D) RT-PCR analysis of Notch-3 and CA-IX mRNA in MCF-7 cells in the presence or absence of anti-IL-6 (1.5 μg/ml) and in shNotch-3 and control-infected MCF-7 cells exposed to DFX (100 μM for 24 hours), Western blot analysis of Notch-3 and β-actin protein. β-2M was assessed as quantitative control for RT-PCR analysis.

activation of Jagged-1, which belongs to a family of Notch ligands (18, 19), and CA-IX, a hypoxia survival gene. Importantly, siRNA knockdown experiments revealed that both Notch-3 and Jagged-1 were functionally required for spheroid formation and for MS self-renewal. Consequently, our data suggest that IL-6 may trigger a potential autocrine/paracrine Notch-3/Jagged-1 loop to boost stem/progenitor self-renewal in the mammary gland. Furthermore, in agreement with previous findings (18, 19, 37), we show that Jagged-1 gene expression correlated with a basal-like breast carcinoma phenotype. Because the IL-6 receptor is expressed at higher levels in basal-like breast carcinomas than in other breast cancer subtypes (34), we hypothesize that the IL-6/Notch-3/Jaggaed-1 axis may confer a growth advantage to basal-like carcinoma cells and also to ductal breast carcinoma stem cells.

We also showed that the CA-IX hypoxia survival gene was upregulated by IL-6 and sustained the invasive potential of breast cancer cells and MS. CA-IX catalyzes carbonic dioxide hydrolysis (44) to facilitate survival under conditions of hypoxia by increasing the concentration of basic equivalents in the cytoplasm, which simultaneously lowers the pH in the extracellular space, thereby creating a favorable environment for the activation of the extracellular matrix degrading enzymes such as MMP-2 (45, 46). Remarkably, higher MMP-2 expression has been associated with poor prognosis in breast cancer (46). In addition, CA-IX hyperexpression has been associated with reduced survival and poor outcome in breast cancer patients (47, 48), and it has also been found to be overexpressed in basal-like breast carcinomas (49, 50). Overall, the upregulation of CA-IX and Jagged-1 adds to a growing number of genes (i.e., CK-5, CK-14, EGFR, CD133, CD44, Bmi-1, and IL-6) that also convey a tight similarity between T-MS and basal-like breast carcinoma. Finally, we present data regarding the autocrine IL-6 loop in breast cancer cells. In particular, we showed that IL-6 upregulated its own mRNA, thus perpetuating the effects of transient IL-6 exposure of breast cancer cells. In addition, this autocrine IL-6 loop required active Notch-3 expression. Hence, our data suggest that the upregulation of IL-6 gene expression in response to stress conditions (hypoxia) or to inflammation (IL-6 itself) may be maintained by an autocrine mechanism in Notch-3 stem/progenitor cells of the mammary gland.

Of note, in this investigation we show that IL-6 triggers self renewal and the invasive capacity of MS obtained from normal mammary tissue. At first glance, this finding could be surprising. However, we must consider that the inflammatory response is a physiologic mechanism aimed at repairing damaged tissues (51). It is therefore conceivable that stem/progenitor cells are able to respond to an inflammatory stimulus (such as IL-6) by a process that promotes proliferation (and self renewal) and stimulates the migration toward locations where tissue repair is required. In this regard, we examined the capacity of MS to generate 3-dimensional structures, that is, to migrate into matrigel and to generate multi-acinar and acinar/ductal structures (ref. 52 and Supplemental Methods). As shown in Supplemental Figure 5, we obtained preliminary evidence that such a morphogenic capacity of MS (upper panel), as well as that of cells derived from the trypsin disaggregation of normal MS (lower panel), may be enhanced by IL-6 administration. Indeed, only in IL-6–administered cultures did we observe features recalling acinar structure with a hollow lumen and ductal branching (arrow and arrowhead, respectively, lower panel). These data, together with those reported previously (24), support the hypothesis that Notch signaling plays a role in mammary gland morphogenesis and therefore suggest that IL-6 may enhance the morphogenic capacity of mammary gland stem/progenitor cells. Instead, we observed that CD44/CK-5–expressing T-MS (Supplemental Figure 6, left panel) plated on plastic and on
Figure 6
The IL-6/Notch-3/CA-IX axis promotes hypoxia survival. (A) MCF-7 cells in the presence or absence of DFX (100 μM for 48 hours) and in the presence or absence of anti–IL-6 (1.5 μg/ml for 24 hours), with transient transfection with the CA-IX–specific or scrambled siRNA (1 μg for 72 hours), and shNotch-3 and control MCF-7 cells. Shown are Western blot analysis of Notch-3 and β-actin protein and cell death analysis and RT-PCR analysis of Notch-3 and CA-IX mRNA (n = 3). *P = 0.017, **P = 0.008, ***P = 0.002, ANOVA. (B) Cell death analysis and RT-PCR analysis of Notch-3 and CA-IX mRNA in day 7 secondary T-MS exposed to 50 μM DFX for 48 hours in the presence or absence of anti–IL-6 (1.5 μg/ml for 48 hours) or anti-N3 (1.5 μg/ml for 48 hours) or transfected with CA-IX or scrambled siRNA (1 μg for 72 hours). n = 3 per group. #P = 0.022, ##P = 0.025, ###P = 0.044, ANOVA. (C) RT-PCR analysis and representative IHC analysis of CA-IX protein expression of breast carcinoma tissues from patients affected by basal-like or ductal breast carcinoma (see Table 2). Data are shown as CA-IX/β2μmRNA ratio. §P = 0.002, Mann-Whitney test. β2μm was assessed as quantitative control for RT-PCR analysis. Scale bar: 100 μm.
matrigel produce cells that lose the expression of some stem cell markers (such as Oct-4 and CK-5) and acquire the expression of CD24, but cannot generate 3-dimensional structures in matrigel (upper right panel), whereas both luminal (CK-18) and myoepithelial (CK-14) markers are expressed (lower right panel). This finding supports the notion that N-MS and T-MS from the same individual have different functional properties and that the latter are endowed with an aberrant/defective capacity to differentiate (24).
It may be indeed argued that the N-MS studied in this investigation were obtained from breast cancer patients. However, although a field effect cannot be completely excluded, it has been recently demonstrated that in the human breast, no detectable changes in gene expression are found when non-neoplastic tissues from cancer patients are compared with normal samples from women without cancer (53). Nevertheless, although it is reasonable that IL-6 could participate in the homeostatic mechanism of a normal mammary gland, it has long been established that chronic inflammation, and the sustained upregulation of its mediators, is a cancer-predisposing condition (51). In this regard, recent data indicate that inflammatory cells such as macrophages and lymphocytes promote cancer growth in the mammary gland (54, 55). Although the role of inflammation in breast cancer has long been criticized, recent experimental and epidemiological data indicate that breast cancer growth may be promoted by local and distant inflammatory processes (such as those in the gut), in agreement with the hypothesis that soluble factors link inflammation to breast cancer (56). In regard to this issue, it is worth mentioning that IL-6 serum levels increase with age (30) and that aging is a major risk factor for breast cancer (57). Hence, we speculate that altered IL-6 gene expression in dysregulated mammary gland/stem progenitor cells...
may be a contributory factor linking aging to breast cancer risk. In conclusion, the findings indicate that IL-6 is a potent promoter of malignant features in Notch-3 expressing normal and tumor stem/progenitor cells of the mammary gland.

**Methods**

**Chemicals and reagents.** Anti–Notch-3, a mAb that blocks the activation of Notch-3 protein by inhibiting the Notch-3/Jagged-1 interaction, was purchased from R&D. Anti–IL-6, a mAb that blocks the IL-6 receptor/ligand interaction, and recombinant human IL-6 were purchased from Sigma-Aldrich. DFX (Sigma-Aldrich) was used as hypoxia mimetic (26); UO-126 (Sigma-Aldrich) was used as MEK1 inhibitor.

**Generation of MS from normal and ductal breast carcinoma tissue specimens.** Seventeen fresh surgical specimens, obtained from patients with ductal breast carcinoma who underwent quadrantectomy or mastectomy, were collected to generate MS (Table 1). Normal and tumor samples were histologically characterized (as reported below) to ensure the proper classification of normal and tumor tissue. Particular care was paid to generate MS from specimens in which only normal or tumor tissues were detectable at histological examination. The set of samples consisted of a subset of tumor specimens (n = 3) in which the mRNA of the tumor tissues from which the MS originated was available as well as a subset of specimens (n = 14) in which even the normal tissue from the same patient was available (Table 1). MS were obtained as previously described (21–27), except that the methodology was downscaled to deal with low amounts of tissues (300–900 mg; ref. 26). Briefly, tissues were placed in sterile Epicult (StemCell Technologies), minced with sterile scalpels, and incubated for 6–12 hours in the presence of 1,000 U Collagenase/Hyaluronidase enzyme mix (StemCell Technologies). Samples were centrifuged at 80 g for 2 minutes, and the pellet was digested by Dispase and DNAse for 3 minutes (StemCell Technologies) and then pelleted.

**Figure 9**

Autocrine IL-6 loop sustains a Notch-3/CA-IX–dependent aggressive phenotype in MCF-7 cells. **(A)** RT-PCR analysis of IL-6 mRNA in MCF-7 cells and N-MS exposed to IL-6 (10 ng/ml) for 24 hours. **(B)** MCF-7 cells exposed to IL-6 (10 ng/ml for 24 hours) and assessed at various times (1 or 2 weeks) after the withdrawal of the cytokine. RT-PCR analysis of IL-6, Notch-3, and CA-IX mRNA and Boyden chamber invasion assay (n = 5) and zymographic analysis (n = 3) of MMP-2 activity (24 hours). *P = 0.010, #P = 0.012, **P = 0.002, ANOVA with post-hoc test for multiple comparisons. **(C)** MCF-7 cells exposed to IL-6 (10 ng/ml) for 24 hours and assessed 2 weeks after cytokine withdrawal in the presence or absence of anti–IL-6 (1.5 μg/ml) for 24 hours. RT-PCR analysis of IL-6, Notch-3, and CA-IX mRNA and Boyden chamber invasion assay (24 hours). n = 5 per group. **P = 0.004, ANOVA with post-hoc test for multiple comparisons. **(D)** RT-PCR analysis of IL-6 and CA-IX mRNA, Western blot analysis of Notch-3 and β-actin protein level, and Boyden chamber invasion assay (24 hours) in shNotch-3 and control MCF-7 cells either untreated or exposed to IL-6 for 24 hours and assessed 2 weeks after cytokine withdrawal (n = 5). ^P = 0.001, ANOVA with post-hoc test for multiple comparisons. **(E)** Boyden chamber invasion assay (24 hours) and RT-PCR analysis of CA-IX mRNA in cells as in C and D transfected with CA-IX or scrambled siRNA (1 μg, 48 hours’ pre-exposure). n = 5 per group. §§P = 0.002, ANOVA. β2μ was assessed as quantitative control for RT-PCR analysis.
Cell death was induced by exposing MCF-7 cells, HYPO-7 cells, and MS to DFX at concentrations of 100, 600, and 1,000 μM, respectively, following previously described protocols (26, 60). Cell death in MS was evaluated by Trypan blue staining of single cells obtained from the trypsin disaggregation of MS, as previously described (26).

**Transient and stable RNA interference.** Double-strand RNA oligonucleotides (siRNA) directed against IL-6 (Stealth validated RNAi DuoPaks), CA-IX, and Jagged-1 (Stealth select 3 RNAi set) mRNA, and appropriate control scrambled siRNAs, were purchased from Invitrogen. siRNAs were transfected to adherent MCF-7 cells (106 cells in a 3-cm2 well) at a concentration of 1 μg/well using Lipofectamine 2000 (Invitrogen). siRNA transfection in MS and MCF-7(S) was performed by mixing 1 μg siRNA with In vitro JET-PEI reagent (Poly plus Transfection). Notch-3-specific siRNA was obtained by cloning an oligonucleotide consisting of a BGI site, a 21- to 22-nt sense sequence (GATCCCCCTCCCTCCACACTATAAAT/TCAAGAGATTATTAGGTTGAGGAGTTTTTGGAAAC), a short spacer (TTCAAGAGA), a 21- to 22-nt antisense sequence ( TCGAGTTTTAACACCTTCCACTTCAAATAAATTCTCTATTTTATTGTTGAGGAGTTTTGGAAAC), and 5 thymidines (a stop signal for RNA polymerase III), and a Xhol site into the psiPuro-Express retention vector (OligoEngine). The same vector encoding for a shRNA that does not match to any human known transcript (5′-GATCCCCAATATCCTCGGTAGCACAGTGTTGTTTATTATTGTGTGTGTCTGGAGGAGTTTTTGGAAAC-3′) was used as control for Notch-3 siRNA. Retroviral gene transfection was performed as follows: Phoenix cells (kindly provided by G. Nolan, Stanford University, Stanford, California, USA) were grown at 60% confluence and were transfected overnight with 30 μg psiPuro-Puro vector encoding a Notch-3 or control shRNA using Lipofectamine 2000 (Invitrogen). Two days after transfection, the medium containing newly packaged retrovirus was collected and filtered through a 0.45-μm pore size filter. After supplementation with 4 μg/ml polybrene (Sigma-Aldrich), the augmented medium was applied to MCF-7 cells at 50% confluence for 24 hours. Successfully infected cells were selected by culturing the cells in presence of 2 μg/ml puromycin for 2 weeks.

**Expression vectors.** The active form of Notch-3, pNIDC3, was cloned by PCR with forward (TCTTGTGCTGTTGCATTCTC) and reverse (GGCCCCCAAAGATCTAAGAGA) primers using Herculase Taq polymerase (Stratagene). The PCR product was inserted into pcDNA3.1/V5-His Topo TA Expression Vector (Invitrogen).

**RT-PCR analysis.** Total RNA was extracted from cultured cells, MS, and archival tissues (n = 19; Table 1, samples 1–3, and Table 2) that had been frozen in liquid nitrogen at the time of surgical resection using the RNA-extracting reagent TRIzol (Invitrogen). Primers used in the RT-PCRs were as follows: IL-6, annealing temperature 62°C, amplicon length 170 bp, forward 5′-GAGAAAGGAGACATGATACAACAGATG-3′, reverse 5′-GGGCAAGAATGAGTAGATTGTG-3′; Notch-3, annealing temperature 62°C, amplicon length 93 bp, forward 5′-TCAGGTCTCACCCTTG-3′, reverse 5′-AGCTATCGAGGAGTTTAGG-3′; CA-IX, annealing temperature 61°C, amplicon length 589 bp, forward 5′-CAGGGGAAACAGGAGGGATGAC-3′, reverse 5′-TTGGAGATGACGCGTCAATG-3′; Bmi-1, annealing temperature 62°C, amplicon length 220 bp, forward 5′-GGAGACCAACAGATGATTTGCCTTTTGT-3′, reverse 5′-CATGCGTGGGCGATGAAG-3′; Jagged-1, annealing temperature 62°C, amplicon length 170 bp, forward 5′-TGGCTGTATCTGTCACACTGTG-3′, reverse 5′-AGCTACGGGGCGCTTTG-3′; TWIST, annealing temperature 55°C, amplicon length 409 bp, forward 5′-TAGTGGTTGCGTCAATGTTG-3′, reverse 5′-GGGAGATGTGAGTTTCG-3′; BCRP-1, annealing temperature 62°C, amplicon length 400 bp, forward 5′-GGTATTCTGTTGTTGCTTTG-3′, reverse 5′-CTGAGCTATAGGGCGCCCTGG-3′; CD44, annealing temperature 62°C, amplicon length 300 bp, forward 5′-CAGACAACCTACATGATGAC-3′, reverse 5′-GCCAAGAGGGATCCGAGAATG-3′; Oct-4, annealing temperature 62°C, amplicon length 169 bp, forward 5′-CTTGCCTGCAGAATGGGTTGAGGAGGAGAA-3′, reverse 5′-TGCCCCGAAAACACACTGCAG-3′.
β3β4, annealing temperature 58°C, amplicon length 180 bp, forward 5'- ACCTCCCAGCTTAAAGATGA-3', reverse 5'-ATCTCCAACCTCCTGATG-3'. PCR primers and reagents were purchased from Invitrogen.

Boyden chamber invasion assay. Cell invasion into Matrigel was assessed by using Boyden chambers (New Technologies Group), containing a polyvinyl-pyrrolidone free polycarbonate filters with 8-μm pores, coated with 15 μg Matrigel (Sigma-Aldrich). Cells (1 x 10⁶) and trypsin-disaggregated MS (1–5 x 10⁶ cells) were seeded in the upper chamber in serum-free medium in the presence or absence of IL-6 (10 ng/ml) or anti-IL-6 (1.5 μg/ml); complete medium was placed in the lower compartment as chemoattractant. In several experiments cells and MS were also transfected with appropriate siRNA for 48 hours and then collected, resuspended in 500 μl in the presence of IL-6 (10 ng/ml) or anti-IL-6 (1.5 μg/ml), and seeded in the upper chamber for 24 hours at 37°C in a 5% CO₂ atmosphere.

At the end of incubation, noninvading cells were removed from the upper surface of the filters, and invading cells in the lower surface were fixed in ice-cold methanol, stained with Toluidine Blue staining (Sigma-Aldrich), and scored as the mean number of invaded cells per 5 random optical fields, in 3 independent experiments, at x20 magnification. Gelatin zymography. MMP-2 activity was determined by gelatin zymography. Briefly, proteins of collected media were precipitated with 1:4 (vol/vol) ice-cold ethanol (1 M Tris-HCl, pH 6.8, 2% SDS, 10% glycerol) and loaded into 10% SDS-polyacrylamide gel containing 1 mg/ml gelatine (Sigma-Aldrich). Gelatin zymography

Western blot. Cell lysates were prepared, run, and blotted using standard methodologies, and probed specific antibodies: rabbit polyclonal anti-Notch-3 (clone M-134; Santa Cruz), mouse mAbs anti-Erk and anti-phosphorylated ERK (Cell Signalling), β-Actin (Sigma-Aldrich), and CA-IX (clone M-75).

Statistics. Continuous variables (percentages of dead cells, number of invading cells in Boyden Chamber assays) were analyzed by ANOVA (unequal variance assumed). Post-hoc test (unequal variance assumed) was used to compare more than 2 groups. Non-normally distributed variables (RT-PCR normalized values of mRNA level) were analyzed by 2-sample nonparametric test (Mann-Whitney). Categorical variables (MS and spheroid size distribution) were analyzed by Monte Carlo χ² test. All the tests were implemented in SPSS 10.1 Package (SPSS). A P value less than 0.05 was considered significant.

Acknowledgments

This work has been supported by University of Bologna RFO funds-ex 60%, Cornelia Pallotti and Roberto Pallotti Foundation to M. Bonafè, and FIRB project RBNE03KZJR to P. Chieco. We also thank Fondazione Cassa di Risparmio in Bologna for supporting the Center for Applied Biomedical Research.

Received for publication April 27, 2007, and accepted in revised form September 12, 2007.

Address correspondence to: Massimiliano Bonafè, Department of Experimental Pathology, Via S. Giacomo 12, 40126, Bologna, Italy. Phone: 39-051-636-4009; Fax: 39-051-636-3902; E-mail: massimiliano.bonafe@unibo.it.